Company overview
Biohit Healthcare, part of Finnish biotech company Biohit Oyj, develops and markets diagnostic products for gastrointestinal diseases, including the blood-based GastroPanel test for Helicobacter pylori infection and atrophic gastritis. They offer point-of-care quick tests, biopsy tests for lactose intolerance and H. pylori, and automated immunoassay analyzers for EIA assays. Solutions support early detection of stomach cancer risks and triage for gastroscopy in clinical settings.
Biohit Healthcare is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include gastropanel, h. pylori test, atrophic gastritis, gi diagnostics, immunoassay analyzer.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.biohithealthcare.com/en/home/
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- gastropanel, h. pylori test, atrophic gastritis, gi diagnostics, immunoassay analyzer
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What diagnostic capabilities does Biohit Healthcare offer for GI disorders?
- Biohit provides GastroPanel for blood-based detection of H. pylori infection and atrophic gastritis, point-of-care quick tests for rapid triage, biopsy tests for lactose intolerance and H. pylori, and automated analyzers for EIA assays.
- What regulatory approvals or intended uses apply to Biohit products?
- Products like GastroPanel are designed as first-line tests for dyspepsia, efficient screening for stomach cancer risks, and triage tools for gastroscopy; some are for research use only unless specified.
- In which geographies does Biohit Healthcare operate?
- Biohit Oyj is headquartered in Helsinki, Finland, with subsidiaries in the UK and Italy, and products trusted worldwide by healthcare professionals.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
